Marksans Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 26 May 2026.

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, marketed by Pfizer Inc.

Benzonatate is a non-narcotic antitussive that works by numbing stretch receptors in the respiratory tract, thereby suppressing the cough reflex. It is commonly used for the symptomatic relief of persistent cough associated with conditions such as bronchitis, pneumonia, and other respiratory infections.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company?s consolidated net profit increased 8.26% year-on-year to Rs 113.20 crore, despite a 10.64% jump in revenue from operations to Rs 754.42 crore in Q3 FY26 compared with Q3 FY25.

Net profit of Marksans Pharma rose 8.26% to Rs 113.20 crore in the quarter ended December 2025 as against Rs 104.56 crore during the previous quarter ended December 2024. Sales rose 10.64% to Rs 754.43 crore in the quarter ended December 2025 as against Rs 681.85 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Profit before tax (PBT) declined 5.13% YoY to Rs 150.62 crore during the quarter.

EBITDA increased 23.2% YoY to Rs 160.7 crore in Q3 FY26, compared with Rs 130.5 crore posted in Q3 FY25. EBITDA margin improved to 21.3% in Q3 FY26 from 19.1% in Q3 FY25.

During the quarter, revenue from the US and North America stood at Rs 412.4 crore (up 16.9% YoY), while revenue from the UK and Europe stood at Rs 258.2 crore (up 0.2% YoY).

Revenue from Australia and New Zealand stood at Rs 61.4 crore (up 30.1% YoY) in Q3 FY26. Revenue from the Rest of the World (RoW) declined 7.2% YoY to Rs 22.4 crore during the period under review.

As of 31 December 2025, the company?s cash balance stood at Rs 824.2 crore. Research and development (R&D) expenditure for 9MFY26 was Rs 62 crore, accounting for 3% of consolidated revenue.

Mark Saldanha, managing director of the company, said, ?We delivered a stable and resilient performance in Q3 FY26, with operating revenue growing 10.6% YoY, supported by steady execution across key markets and improved seasonal demand. Margins expanded sequentially, driven by soft raw material costs, favorable currency movements, and an improving product mix, while EBITDA growth reflected operating leverage.

During the quarter, we took measured steps to strengthen our global footprint through new subsidiaries in Europe and Canada, positioning the company for long-term growth in regulated markets. We remain disciplined, execution-focused, and committed to delivering sustainable growth and long-term shareholder value.?

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

Powered by Capital Market - Live News